Atlas Trials

Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease

Clinical trial NCT05663827 · COMPLETED

Trial details

NCT number
NCT05663827
Sponsor
Yi-Lun Wang
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Steroid Refractory GVHD
Start date
2019-01-01
Primary completion
2020-01-01
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.